Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 6/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627408 | 0.89 | NTRK1 (0.35) | RPA1MGLLMALT1 | |
| SCHEMBL2914144 | 0.84 | MALT1 (0.53) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2915301 | 0.82 | RPA1 (0.49) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2917950 | 0.81 | MGLL (0.51) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2921226 | 0.81 | RPA1 (0.50) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2920011 | 0.80 | MGLL (0.46) | RPA1MGLLMEN1KMT2AMDM2 | |
| SCHEMBL2910437 | 0.79 | RPA1 (0.70) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL2918416 | 0.78 | RPA1 (0.47) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2911599 | 0.78 | RPA1 (0.47) | RPA1MGLLMALT1MEN1KMT2A | |
| SCHEMBL2920304 | 0.78 | RPA1 (0.47) | RPA1MGLLMEN1KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | RPA1 4200/4885MGLL 2165/4885MALT1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.